Roche Strikes $2.3 Billion Nurix Blood Cancer Drug Deal for Bexobrutideg
Updated
Updated · Reuters · Jun 8
Roche Strikes $2.3 Billion Nurix Blood Cancer Drug Deal for Bexobrutideg
3 articles · Updated · Reuters · Jun 8
Summary
$700 million upfront will go to Nurix under Roche’s exclusive licensing and collaboration agreement for bexobrutideg, a blood cancer drug slated to enter Phase III testing in chronic lymphocytic leukemia this summer.
The pact could reach $2.3 billion with development, regulatory and sales milestones, giving Roche a new late-stage candidate built on targeted protein degradation.
Roche will fund 60% of development costs and Nurix 40%, while the companies will co-commercialize the drug in the U.S. and split profits and losses equally.
Outside the U.S., Roche will handle commercialization and pay Nurix royalties; the deal is expected to close in the third quarter of 2026.
Is Roche's $2.3 billion deal a visionary leap for cancer therapy or a high-stakes gamble on unproven technology?
Can a new drug that 'deletes' cancer proteins finally offer hope to leukemia patients for whom other treatments have failed?
Could this protein-degrading technology become the next major breakthrough for autoimmune diseases like multiple sclerosis?
Roche and Nurix Forge $2 Billion Alliance to Advance Bexobrutideg, a Next-Generation BTK Degrader for Cancer and Autoimmune Diseases
Overview
Roche and Nurix Therapeutics have formed a major strategic alliance, announcing a $2 billion cancer drug agreement in June 2026 focused on developing bexobrutideg, a novel BTK degrader. The deal’s completion depends on standard closing conditions, including regulatory review, with both companies expecting to finalize the partnership by the third quarter of 2026. This collaboration marks a clear timeline for launching their joint efforts, aiming to advance innovative cancer therapies and address unmet medical needs in oncology.